Metall Zug AG (METN) Fair Value & Analysis
Healthcare · CH · Market cap CHF 326M
Fair value as of: Aug 13, 2026
From 3 valuation models · updated yesterday
Fair value updated Aug 13, 2026, revised from CHF 575.01 to CHF 572.27 (−0.5%) since Jul 16, 2026. Share price +13.9% over the past month.
Below-average quality, and screening another 31% overvalued on our models.
What matters now
- Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (CHF 427.07 to CHF 854.13) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range CHF 697.00 – CHF 2,079 · fair‑value band CHF 427.07 – CHF 854.13 · the CHF 829.00 price screens above the CHF 572.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Metall Zug AG (METN) currently trades at CHF 829.00, while our model-based Fair Value estimate is CHF 572.27, implying the stock looks roughly 31.0% overvalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Metall Zug AG generated revenue of CHF 195M at a net margin of -7.8%. Revenue declined 1.8% year over year. It earns a return on equity of -3.6%. Net debt stands at CHF 137M. Fundamentals as of Aug 13, 2026
Our scenario range runs from CHF 427.07 (bear case) to CHF 854.13 (bull case); at CHF 829.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 22% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -31%, METN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (CHF 575.01) versus Dividend Discount (CHF 167.32). Highest evidence: Gordon GGM (70).
Notify me when METN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Metall Zug AG, through its subsidiaries, engages in the medical devices, infection control, technology cluster and infrastructure, and other businesses in Switzerland, Europe, North America, South America, the Asia Pacific, and internationally.
Full company description
Metall Zug AG, through its subsidiaries, engages in the medical devices, infection control, technology cluster and infrastructure, and other businesses in Switzerland, Europe, North America, South America, the Asia Pacific, and internationally. The company develops, manufactures, and distributes devices and solutions for medical diagnosis, microsurgery, and eye training. It also offers diagnostics equipment, such as slit lamps, tonometry devices, and perimetry and biometry equipment for cataract diagnosis and treatment; equipment for ophthalmologists, including tables, chairs, and industrial high-precision surgical microscopes; accessories, including measuring instruments for precision optics, lenses, software solutions, and comprehensive services; and augmented and virtual reality technology and digital imaging for the training and further education of eye care specialists. In addition, the company supplies dishwashers, thermal appliances, and cleaning agents for catering and hotel sectors. Further, it engages in the management and development of real estate. The company was formerly known as Metallwaren-Holding AG and changed its name to Metall Zug AG in September 2002. Metall Zug AG was founded in 1887 and is headquartered in Zug, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Metall Zug AG reported revenue of CHF 195M in FY2025 versus CHF 662M in FY2021, a compound −26.4%/yr. Reported net income was −CHF 15.2M in FY2025.
of which total revenue −9.7 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
METN screens 31% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 346 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Metall Zug AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Metall Zug AG (METN) overvalued or undervalued?
What is the fair value of METN?
What is the quality score of METN?
What is the revenue of Metall Zug AG (METN)?
What is the net profit margin of METN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Metall Zug AG and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.